Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Argenx Se (ARGX – Research Report), GoodRx Holdings (GDRX – Research Report) and Annexon Biosciences (ANNX – Research Report).
Argenx Se (ARGX)
UBS analyst Xian Deng maintained a Hold rating on Argenx Se today and set a price target of $410.00. The company’s shares closed last Thursday at $380.01.
Deng has an average return of
According to TipRanks.com, Deng is ranked #852 out of 8757 analysts.
Currently, the analyst consensus on Argenx Se is a Strong Buy with an average price target of $480.26.
See Insiders’ Hot Stocks on TipRanks >>
GoodRx Holdings (GDRX)
In a report released today, Lisa Gill from J.P. Morgan upgraded GoodRx Holdings to Buy, with a price target of $10.00. The company’s shares closed last Thursday at $7.79.
According to TipRanks.com, Gill is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for GoodRx Holdings with a $8.15 average price target, a 12.1% upside from current levels. In a report issued on February 26, Leerink Partners also initiated coverage with a Buy rating on the stock with a $8.00 price target.
Annexon Biosciences (ANNX)
In a report released today, Anupam Rama from J.P. Morgan upgraded Annexon Biosciences to Buy, with a price target of $11.00. The company’s shares closed last Thursday at $5.57.
According to TipRanks.com, Rama is a 5-star analyst with an average return of
Currently, the analyst consensus on Annexon Biosciences is a Strong Buy with an average price target of $14.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARGX:
- argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- ARGX Upcoming Earnings Report: What to Expect?
- argenx to Present at Upcoming Investor Conferences
- argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
- Argenx announces FDA acceptance of Vyvgart Hytrulo sBLA for priority review
